Back to search

Article

Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shade

2024-03-01

Abstract excerpt

Antisense oligonucleotides (ASOs) are short oligodeoxynucleotides designed to bind to specific regions of target mRNA. ASOs can modulate pre-mRNA splicing, increase levels of functional proteins and decrease levels of toxic proteins. ASOs are being developed for the treatment of several diseases, including motor neuron diseases (MNDs), a group of neurodegenerative disorders characterised by the loss of motor neuro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5babda5c-9a03-5313-b5d8-7e20a8638001
DOI
10.20944/preprints202402.1738.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shadeDOI 10.20944/preprints202402.1738.v1
Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and ShadeSemantic proximity
Therapeutic antisense oligonucleotides for movement disordersSemantic proximity
Recent Progress of Antisense Oligonucleotide Therapy for Superoxide Dismutase 1-mutated Amyotrophic Lateral Sclerosis: Focus on TofersenSemantic proximity
Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscapeSemantic proximity
The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySemantic proximity
Antisense Drugs Make Sense for Neurological DiseasesSemantic proximity
Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen.Semantic proximity
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s diseaseSemantic proximity
Oligonucleotide therapeutics in neurodegenerative diseasesSemantic proximity
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseasesSemantic proximity
Challenges and future perspective of antisense therapy for spinal muscular atrophy: A reviewSemantic proximity
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disordersSemantic proximity
Select a neighboring publication to make it the new centre.